Abstract
Biofilm infections are extremely hard to eradicate and controlled, triggered and controlled drug release properties may prolong drug release time. In this study, the ability to externally control drug release from micro and nanoparticles was investigated. We prepared micro/nanoparticles containing ciprofloxacin (CIP) and magnetic nanoparticles encapsulated in poly (lactic-co-glycolic acid) PLGA. Both micro/nanoparticles were observed to have narrow size distributions. We investigated and compared their passive and externally triggered drug release properties based on their different encapsulation structures for the nano and micro systems. In passive release studies, CIP demonstrated a fast rate of release in first 2 days which then slowed and sustained release for approximately 4 weeks. Significantly, magnetic nanoparticles containing systems all showed ability to have triggered drug release when exposed to an external oscillating magnetic field (OMF). An experiment where the OMF was turned on and off also confirmed the ability to control the drug release in a pulsatile manner. The magnetically triggered release resulted in a 2-fold drug release increase compared with normal passive release. To confirm drug integrity following release, the antibacterial activity of released drug was evaluated in Pseudomonas aeruginosa biofilms in vitro. CIP maintained its antimicrobial activity after encapsulation and triggered release.
Highlights
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacterium belonging to the bacterial family pseudomonadaceae
For Ciprofloxacin hydrochloride (CIP) encapsulated in PLGA magnetic microparticles preparation, the secondary emulsification was performed by homogenizing the water-in-oil (W/O) emulsion with 20.0 mL 2% Polyvinyl Alcohol (PVA) solution at 15,000 rpm 10 min
CIP encapsulated in PLGA magnetic particles were prepared using a double emulsion technique
Summary
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacterium belonging to the bacterial family pseudomonadaceae. Triggered-Release of Drug from PLGA Micro and Nanoparticles soft tissue infections, pneumonias and urinary tract infections [1]. Ciprofloxacin hydrochloride (CIP) is a widely used antibiotic drug against a broad range of clinically relevant Gram-negative and Gram-positive pathogens infections. Urinary tract infections required twice daily at doses of 250 mg or oncedaily extended-release ciprofloxacin; a current treatment regimen of cystic fibrosis requires ciprofloxacin at least twice-a-day administration at a dose of 300 mg for alternating 28-day on-off cycles [4]. Aminoglycoside therapy of cystic fibrosis lung infections may be realized if delivery of sufficient drug at sustained levels in and around the target infections could be achieved [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
